News Release

Genes & Cancer | Leveraging allogeneic dendritic cells for neoantigen cancer vaccines

Peer-Reviewed Publication

Impact Journals LLC

Figure 3

image: Figure 3: The use of PDC*vac platform to develop NeoAg-based cancer vaccines. view more 

Credit: 2023 Hannani et al.

BUFFALO, NY- February 3, 2023 – A new research perspective was published in Genes & Cancer on January 30, 2023, entitled, “Leveraging a powerful allogeneic dendritic cell line towards neoantigen-based cancer vaccines.”

In recent years, immunotherapy has finally found its place in the anti-cancer therapeutic arsenal, even becoming standard of care as first line treatment for metastatic forms. The clinical benefit provided by checkpoint blockers such as anti-PD-1/PD-L1 in many cancers revolutionized the field. However, too many patients remain refractory to these treatments due to weak baseline anti-cancer immunity. 

There is therefore a need to boost the frequency and function of patients’ cytotoxic CD8+ cellular effectors by targeting immunogenic and tumor-restricted antigens, such as neoantigens using an efficient vaccination platform. Dendritic cells (DC) are the most powerful immune cell subset for triggering cellular immune response. However, autologous DC-based vaccines display several limitations, such as the lack of reproducibility and the limited number of cells that can be manufactured. 

In this new research perspective, researchers Dalil Hannani, Estelle Leplus, Karine Laulagnier, Laurence Chaperot, and Joël Plumas from PDC*line Pharma and Etablissement Français du Sang Auvergne Rhône-Alpes (EFS AURA) discuss the advantages of a new therapeutic vaccine based on an allogeneic Plasmacytoid DC cell line, which is easy to produce and represents a powerful platform for priming and expanding anti-neoantigen cytotoxic CD8+ T-cells.

“NeoAgs appear attractive candidates to induce specific anti-tumor responses in cancer patients, on top of classical tumor-associated antigens and in association with ICIs. A potent dendritic cell product such as PDC*neo represents a valuable platform to develop NeoAg-based cancer vaccines (Figure 3). We strongly believe that this new delivery technology based on potent PDC*line cells can induce a robust anti-NeoAg CD8+ T-cell immune response for the benefit of patients and could reshape the landscape of NeoAg-based cancer vaccines.”

Read the full research paper: DOI: 

Correspondence: Joël Plumas - Email: 

Keywords: cancer vaccine, neoantigens, plasmacytoid dendritic cells, immunotherapy

About Genes & Cancer: Genes & Cancer covers all aspects of the structure and function of oncogenes, growth suppressor and apoptotic genes, their role in signal transduction and the mechanisms by which their expression and function are altered during tumor development. In addition to publishing manuscripts that directly relate to these areas of research, Genes & Cancer also aims to attract papers in the areas of genomics, drug development and systems biology.

To learn more about Genes & Cancer, visit and connect with us on social media:


For media inquiries, please contact:


Genes & Cancer Journal Office

6666 East Quaker Str., Suite 1C

Orchard Park, NY 14127

Phone: 1-212-659-5400


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.